|
GSK2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanoma |
GSK2132231A |
111482 |
NCT00796445 2008-002447-16 |
Melanoma |
Phase 3 |
|
|
|
|
An annotated case report form is not available for this study. A blank case report form will be provided. |
May 2018 |